Esperion Therapeutics financials at a glance
| Year | Year | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2012 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rev. | Revenue |
|
$0.00M | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M | $148.36M | $227.55M | $78.45M | $75.48M | $116.33M | $0.00M | $0.00M |
| GM % | Gross Margin % |
|
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -18.36% | 34.37% | -53.21% | -93.30% | -11.21% | 0.00% | 0.00% |
| OM | Operating Margin |
|
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -62.75% | -53.35% | -272.13% | -237.83% | -133.72% | 0.00% | 0.00% |
| EPS | Earnings Per Share |
|
$-2.98 | $-2.22 | $-2.26 | $-3.33 | $-6.98 | $-7.54 | $-3.59 | $-5.23 | $-9.31 | $-3.52 | $-2.03 | $0.00 | |
| Div. | Dividends |
|
$0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| PR % | Payout Ratio % |
|
-0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | 0 | 0 |
| Sha. | Shares |
|
15.34m | 20.34m | 22.51m | 22.55m | 26.2m | 26.81m | 27.33m | 27.88m | 61.22m | 62.98m | 113.72m | 0m | 170.42m |
| OCF | Operating Cash Flow |
|
$-18.11M | $-32.02M | $-38.16M | $-47.73M | $-131.30M | $-148.64M | $-70.34M | $-85.18M | $-263.81M | $-174.83M | $-135.49M | $-10.81M | $0.00M |
| FCF | Free Cash Flow |
|
$-18.14M | $-32.89M | $-38.48M | $-47.82M | $-131.32M | $-148.79M | $-71.29M | $-86.05M | $-263.81M | $-174.83M | $-65.00M | $-10.82M | $0.00M |
| FCFS | Free Cash Flow Per Share |
|
$-2.30 | $-2.01 | $-1.75 | $-2.12 | $-5.49 | $-5.56 | $-2.63 | $-3.59 | $-9.13 | $-2.63 | $-1.31 | $-33.44 | $0.00 |